Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ovid Therapeutics, Inc.

http://www.ovidrx.com/

Latest From Ovid Therapeutics, Inc.

Minute Insight: What Is Going On With Butterfly Network’s Leadership?

Since going public, the company’s share price has flopped, its board has seen a flurry of appointments and resignations over the past year, and now the company is facing investor lawsuits.

Minute Insights Legal Issues

Finance Watch: Biopharma IPO Market Silence Continues In The US

Public Company Edition: The last biopharma IPO in the US was on 17 February and none have been scheduled, so far, for March. Also, another SPAC merger is called off, Travere sells $275m worth of notes and Xeris secures $150m in new debt, while Ovid, Passage Bio and others are cutting jobs. 

Financing Business Strategies

Silicon Valley Bank Advisor Predicts 2022 Will Be Year For Healthtech, Massive Consolidation

SVB health care advisor Jonathan Norris anticipates more consolidation in devices ahead with many mid-cap public companies looking to acquire innovative technologies to grow, and pushing the “big guys to have to figure out how to move faster.”

Financing M & A

Exec Chat: Clarius' Take On The Emerging Handheld Ultrasound Market

In an interview with Medtech Insight, Another newcomer to the handheld ultrasound market weighed in on the competitive environment.

Exec Chats Digital Health
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register